XML 20 R5.htm IDEA: XBRL DOCUMENT v3.19.1
Statement Of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Cash Flows From Operating Activities:    
Net (Loss) $ (2,156,155) $ (1,040,236)
Amortization & Depreciation 49,361 6,629
Foreign exchange gain (42,399) 0
Stock issued for services 676,100 427,400
Loss on conversion of notes payable 871,973 76,929
Stock issued for payment of interest 33,977 3,022
Interest forgiven (247) 0
Increase (decrease) in accounts receivable (15,447) 0
(Increase) decrease in prepaid expenses 8,326 (8,660)
Increase (decrease) in Accounts Payable 61,629 (8,808)
Increase (decrease) in interest payable 76 204
Net Cash Flows (Used) in Operations (512,806) (543,520)
Cash Flows From Investing Activities:    
Cash received from purchase of subsidiary 4,942 0
Purchase equipment (18,850) (3,718)
Deposits on business acquisition 0 (80,290)
Net Cash Flows (Used) in Investing Activities (13,908) (84,008)
Cash Flows From Financing Activities:    
Proceed from note payable 609,885 660,565
Notes Payable - Interest expense 26,759 33,977
Payment of notes payable (194,184) (115,000)
Note payable - related party 29,930 2,251
Note payable used to pay expenses 36,500 0
Note payable used to pay origination fees & interest 18,750 25,000
Sale of common stock 0 63,912
Net Cash Flows Provided by Financing Activities 527,640 670,705
Net Increase (Decrease) In Cash and cash equivalents 926 43,177
Foreign currency translation adjustment 6,758 6,902
Cash and cash equivalents at beginning of period 107,532 57,453
Cash and cash equivalents at end of period 115,216 107,532
Supplementary Disclosure Of Cash Flow Information:    
Cash paid for interest 23,496 21,900
Stock issued for acquisition of Atlas Pharma Inc. 238,000 0
Stock issued for services 676,100 427,400
Stock issued for note and accrued interest conversions 1,589,099 128,451
Stock issued to buy equipment 174,808 56,700
Loan issued for interest $ 45,509 $ 58,977